or Try an Advanced Search...

    Technical Analysis for ALXO - ALX Oncology Holdings Inc.

    Grade Last Price % Change Price Change
    F 5.99 -0.66% -0.04
    ALXO closed down 0.66 percent on Monday, July 1, 2024, on 82 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ALXO trend table...
    Date Alert Name Type % Chg
    1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Bullish Engulfing Bullish -0.66%
    Pocket Pivot Bullish Swing Setup -0.66%
    Volume Surge Other -0.66%
    Outside Day Range Expansion -0.66%
    Older End-of-Day Signals for ALXO ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 10 hours ago
    Up 3% about 10 hours ago
    Up 2% about 10 hours ago
    Reversed from Down about 10 hours ago
    Gap Down Partially Closed about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ALXO Chart by TradingView
    Basic chart:

    Profile

    ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Cancer Immunotherapy Acute Myeloid Leukemia Carcinoma Epidermal Growth Factor Receptor Myelodysplastic Syndrome Syndromes Treatment Of Myelodysplastic Syndrome

    Is ALXO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 1 Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
    Jul 1 PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
    Jun 28 Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
    Jun 27 Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
    Jun 27 Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
    Jun 27 ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
    Jun 26 ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
    Jun 25 Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
    Jun 25 Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
    Jun 24 Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
    See more ALXO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.825
    52 Week Low 3.9357
    Average Volume 819,104
    200-Day Moving Average 11.47
    50-Day Moving Average 12.05
    20-Day Moving Average 7.56
    10-Day Moving Average 6.46
    Average True Range 0.78
    RSI (14) 21.26
    ADX 48.32
    +DI 7.48
    -DI 34.37
    Chandelier Exit (Long, 3 ATRs) 8.88
    Chandelier Exit (Short, 3 ATRs) 7.89
    Upper Bollinger Bands 9.93
    Lower Bollinger Band 5.20
    Percent B (%b) 0.17
    BandWidth 62.46
    MACD Line -1.69
    MACD Signal Line -1.73
    MACD Histogram 0.035
    Fundamentals Value
    Market Cap 298.41 Million
    Num Shares 49.8 Million
    EPS -3.57
    Price-to-Earnings (P/E) Ratio -1.68
    Price-to-Sales 5906.24
    Price-to-Book 4.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 6.71
    Resistance 3 (R3) 6.72 6.48 6.59
    Resistance 2 (R2) 6.48 6.30 6.48 6.55
    Resistance 1 (R1) 6.24 6.19 6.36 6.23 6.51
    Pivot Point 6.00 6.00 6.07 6.00 6.00
    Support 1 (S1) 5.76 5.82 5.88 5.75 5.47
    Support 2 (S2) 5.52 5.71 5.52 5.43
    Support 3 (S3) 5.28 5.52 5.39
    Support 4 (S4) 5.27